Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of 14C-Bleximenib in Acute Leukemia
NCT07295951Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bleximenib in acute leukemia, sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Dose Excreted in Urine, Percentage of Dose Excreted in Feces and 4 more. Started Nov 2025; status: completed.
02
Drugs
bleximenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT07295951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295951.